Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
ARVINAS, INC. reported that Chief Medical Officer Noah Berkowitz received new equity awards. He was granted stock options for 67,000 shares at an exercise price of $0.0000 per share and 45,000 restricted stock units, each representing one share of common stock upon settlement for no consideration.
The RSUs vest in four equal annual installments on February 26, 2027, 2028, 2029 and 2030, subject to continued service. The option also vests over four years, with one-quarter vesting on February 26, 2027 and the remainder in equal monthly installments through February 26, 2030. Following these grants, Berkowitz directly owns 208,938 shares of common stock.
Saik Andrew reported acquisition or exercise transactions in this Form 4 filing.
Arvinas, Inc. reported that its Chief Financial Officer, Andrew Saik, received equity awards on February 26, 2026. He was granted options to purchase 67,000 shares and 45,000 restricted stock units, both at no cash cost, vesting gradually over four years, contingent on continued service.
Arvinas, Inc. President and CEO Randy Teel reported equity awards from the company. He received a stock option for 218,691 shares at an exercise price of $0.00 per share and a grant of 147,791 restricted stock units, each settling into one common share if vesting conditions are met. Both awards vest over four years starting on February 12, 2027, contingent on his continued service.
Arvinas, Inc. director John G. Houston reported selling a total of 35,297 shares of common stock on February 27, 2026 in three open‑market transactions at prices between $13.14 and $13.24 per share.
According to the footnotes, each sale was made automatically by Arvinas to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units, and the sales did not represent discretionary trades. After these transactions, Houston directly owned 1,122,183 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock tied to tax withholding. On February 23, he sold 1,108 shares of Arvinas common stock at $12.16 per share. The sale was made by the company to cover tax obligations arising from the vesting and settlement of one-half of his restricted stock units granted on February 23, 2024, and did not represent a discretionary trade. After this transaction, Loomis directly holds 29,692 Arvinas common shares.
ARVINAS, INC. Chief Scientific Officer Angela M. Cacace reported automatic sales of a total of 3,609 shares of common stock at $12.16 per share. These transactions were made by the company to cover tax withholding on vesting restricted stock units and did not represent discretionary trades.
Arvinas, Inc. President and CEO Randy Teel reported two open-market sales of common stock linked to equity award vesting. On February 23, 2026, he sold 1,038 shares and 3,748 shares at $12.16 per share, totaling 4,786 shares.
According to the footnotes, both sales were made automatically by the company to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on February 22, 2023 and February 23, 2024, and do not represent discretionary trades.
Arvinas, Inc. reports a year focused on advancing its PROTAC protein degradation pipeline while remaining deeply loss‑making. The company is still pre‑revenue from product sales and recorded net losses of $80.8 million in 2025, $198.9 million in 2024 and $367.3 million in 2023, and expects operating losses for at least several more years.
Its most advanced candidate, vepdegestrant, has a New Drug Application accepted by the FDA for ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer, with a PDUFA action date of June 5, 2026. Arvinas highlights a broad clinical pipeline, including ARV‑102 for Parkinson’s disease and PSP, ARV‑806 for KRAS G12D‑mutated solid tumors, ARV‑393 for non‑Hodgkin lymphoma and ARV‑027 for spinal bulbar muscular atrophy, plus multiple preclinical neurology, oncology, and immuno‑oncology programs. Management believes existing cash, cash equivalents and marketable securities can fund planned operations into the second half of 2028, but substantial additional capital will ultimately be required.
Arvinas, Inc. reported 2025 results showing a sharply reduced net loss and a stronger balance sheet to support its PROTAC pipeline. Full-year revenue was $262.6 million, roughly flat with 2024, while the net loss narrowed to $80.8 million from $198.9 million as both R&D and G&A expenses declined.
Year-end cash, cash equivalents and marketable securities totaled $685.4 million, and the company expects this to fund operations into the second half of 2028. Arvinas highlighted multiple clinical programs, including ARV-102, ARV-806, ARV-393, ARV-027 and ARV-6723, as well as vepdegestrant, which has an FDA PDUFA action date of June 5, 2026.
The company also appointed Randy Teel, Ph.D., as President and CEO, continued progressing four ongoing clinical trials, initiated a Phase 1 study for ARV-027, and prepared to move its first immuno-oncology candidate ARV-6723 into the clinic, underscoring an active late- and mid-stage pipeline.